Aktis Oncology
Update in progressAKTS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Aktis Oncology, Inc. is a clinical-stage oncology company developing targeted radiopharmaceuticals for solid tumors. Its lead candidates are [225Ac]Ac-AKY-1189, in Phase 1b for Nectin-4–expressing tumors (including urothelial, breast, NSCLC, colorectal, and cervical cancers), and [225Ac]Ac-AKY-2519 for B7-H3–expressing tumors (e.g., prostate and lung cancers). It has licenses with Protein Innovation, TRIUMF Innovations, and Eli Lilly. Formerly HotKnot Therapeutics, renamed in 2020; founded 2020 and based in Boston.
Company score
- Sentiment
- -0.61
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- -0.42
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.35
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Matthew Roden Ph.D.
- Founded2020
- Employees79
- Websitewww.aktisoncology.com
Identifiers
- ISINUS01021M1045
- FIGIBBG00ZQS8KZ1